Pharmacokinetics and Pharmacodynamics — MCQs
Which of the following statements is true regarding competitive reversible antagonism?
Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -
A patient named Ram Prasad is admitted to Guru Teg Bahadur Hospital with a respiratory infection. Tobramycin is ordered for treatment. Given that the clearance and volume of distribution of tobramycin in him are 160 mL/min and 40 L, respectively, calculate the intravenous loading dose required to achieve a therapeutic plasma concentration of 4 mg/L.
At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?
Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?
Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?
Which of the following statements is true about first-order kinetics?
A 55-year-old man presents with a tremor that occurs when his hands are at rest. He has a slow, shuffling gait and difficulty initiating movement. His symptoms improve with levodopa. What is the most likely diagnosis?
Which one of the following causes low-volume erythrocytosis?
A diabetic female on Isoniazid (INH) and Rifampicin for tuberculosis developed Deep Vein Thrombosis (DVT). She was started on Warfarin, but her Prothrombin Time (PT) is not elevated. What is the next appropriate step in management?
Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following statements is true regarding competitive reversible antagonism?
- A. ED50 remains unchanged in competitive reversible antagonism.
- B. Efficacy and Vmax remain unchanged. (Correct Answer)
- C. Potency remains unchanged in the presence of a competitive antagonist.
- D. Affinity (Kd) remains unchanged in competitive reversible antagonism.
Explanation: ***Efficacy and Vmax remain unchanged.*** - In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2]. - The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor. - This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2]. *Potency remains unchanged in the presence of a competitive antagonist.* - **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3]. - A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4]. - The dose-response curve shifts to the right (parallel shift) [4]. *ED50 remains unchanged in competitive reversible antagonism.* - **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect. - Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4]. *Affinity (Kd) remains unchanged in competitive reversible antagonism.* - The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1]. - In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy. - The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.
Question 2: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -
- A. 1 gm
- B. 5 gm
- C. 25 gm
- D. 12.5 gm (Correct Answer)
Explanation: ***12.5 gm*** - The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability. - Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2. - So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**. *1 gm* - This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor. - It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution. *5 gm* - This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation. - This option does not correctly factor in the **20% bioavailability** of the administered drug. *25 gm* - This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it. - This answer significantly **overestimates** the required dose, which could lead to drug toxicity.
Question 3: A patient named Ram Prasad is admitted to Guru Teg Bahadur Hospital with a respiratory infection. Tobramycin is ordered for treatment. Given that the clearance and volume of distribution of tobramycin in him are 160 mL/min and 40 L, respectively, calculate the intravenous loading dose required to achieve a therapeutic plasma concentration of 4 mg/L.
- A. 0.1 mg
- B. 10 mg
- C. 115.2 mg
- D. 160 mg (Correct Answer)
Explanation: ***160 mg*** - The loading dose is calculated using the formula: **Loading Dose = Volume of Distribution (Vd) × Target Plasma Concentration (Cp)**. - Given Vd = 40 L and Cp = 4 mg/L, the calculation is 40 L × 4 mg/L = **160 mg**. *0.1 mg* - This value is significantly too low for a therapeutic loading dose of tobramycin and would not achieve the desired concentration. - It likely results from incorrect units or a miscalculation of the formula. *10 mg* - This dose is too low to reach the therapeutic plasma concentration of 4 mg/L given the patient's volume of distribution. - It suggests a calculation error, possibly dividing Vd by Cp instead of multiplying. *115.2 mg* - This value indicates a calculation error, as it does not correspond to the correct application of the loading dose formula. - It might arise from using an incorrect volume of distribution or target concentration, or an error in multiplication.
Question 4: At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?
- A. Absorption of drug is 50% ionic and 50% non-ionic
- B. Conc. of drug is 25% ionic and 75% non-ionic
- C. Conc. of drug is 75% ionic and 25% non-ionic
- D. Conc. of drug is 50% ionic and 50% non-ionic (Correct Answer)
Explanation: ***Conc. of drug is 50% ionic and 50% non-ionic*** - At **pKa = pH**, the concentrations of the **ionized** and **unionized** forms of a drug are equal as per the **Henderson-Hasselbalch equation**. - This means that exactly **half** of the drug molecules are in their charged (ionic) state, and the other half are in their uncharged (non-ionic) state. *Absorption of drug is 50% ionic and 50% non-ionic* - The amount of drug that is absorbed is dependent on the **non-ionic concentration** available at the absorption site, but this option incorrectly states that the *absorption itself* is 50% ionic. - Absorption primarily occurs for the **non-ionic, lipophilic form** as it can more readily cross cell membranes. *Conc. of drug is 75% ionic and 25% non-ionic* - This ratio would occur when the **pH** is either 0.5 units above the pKa for a weak acid or 0.5 units below the pKa for a weak base. - For example, if **pH = pKa + 0.5** (for a weak acid), approximately 75% would be ionic. *Conc. of drug is 25% ionic and 75% non-ionic* - This ratio would occur when the **pH** is either 0.5 units below the pKa for a weak acid or 0.5 units above the pKa for a weak base. - For example, if **pH = pKa - 0.5** (for a weak acid), approximately 25% would be ionic.
Question 5: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?
- A. ED50 of the drug corresponds to efficacy (Correct Answer)
- B. Drugs that produce a similar pharmacological effect can have different levels of efficacy
- C. In a clinical setup, efficacy is more important than potency
- D. In the log dose response curve, the height of the curve corresponds with efficacy
Explanation: ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.
Question 6: Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?
- A. Clearance
- B. Volume of distribution (Correct Answer)
- C. Half-life
- D. Bioavailability
- E. Elimination rate constant
Explanation: ***Volume of distribution*** - The **loading dose** of a drug is primarily determined by its **volume of distribution (Vd)** and the **target plasma concentration**. - A larger **Vd** means the drug distributes widely into tissues, requiring a larger loading dose to achieve the desired concentration in the central compartment. *Clearance* - **Clearance** dictates the **maintenance dose** needed to sustain a steady-state concentration once the loading dose has been administered. - It reflects the rate at which the drug is eliminated from the body, not how much is initially needed to fill the distribution volume. *Half-life* - **Half-life** determines the **time required to reach steady-state** and the **dosing interval** for maintaining therapeutic concentrations. - While related to clearance and Vd, it does not directly determine the magnitude of the initial loading dose itself. *Bioavailability* - **Bioavailability** is the fraction of administered drug that reaches the systemic circulation in an unchanged form. - It influences the oral dose required to achieve a certain plasma concentration, but the concept of loading dose is typically considered for the intravenous route where bioavailability is 100%. *Elimination rate constant* - The **elimination rate constant (ke)** describes the rate of drug elimination and is related to clearance and volume of distribution (ke = Cl/Vd). - Like clearance, it determines the **maintenance dose** and dosing frequency, not the initial loading dose required to achieve therapeutic levels.
Question 7: Which of the following statements is true about first-order kinetics?
- A. The half-life increases with an increase in dose.
- B. The rate of elimination is proportional to the plasma concentration. (Correct Answer)
- C. A constant amount is eliminated in unit time.
- D. The elimination follows zero-order kinetics at therapeutic doses.
Explanation: ***The rate of elimination is proportional to the plasma concentration.*** - In **first-order kinetics**, a **constant fraction** of the drug is eliminated per unit of time, meaning that the higher the plasma concentration, the faster the elimination rate. - This principle ensures that the drug concentration decreases exponentially over time, as the amount eliminated is always a percentage of the remaining drug. - The rate equation is: dC/dt = -kC, where the rate is directly proportional to concentration. *The half-life increases with an increase in dose.* - This statement is incorrect because, for **first-order kinetics**, the **half-life remains constant** regardless of the dose or the initial concentration of the drug. - The time it takes for the plasma concentration to halve is independent of the initial amount. *The elimination follows zero-order kinetics at therapeutic doses.* - This is incorrect. **First-order kinetics** is the most common pattern for drug elimination at **therapeutic doses**. - **Zero-order kinetics** occurs when elimination mechanisms become **saturated**, typically at very high doses (e.g., phenytoin, ethanol, aspirin at high doses). *A constant amount is eliminated in unit time.* - This describes **zero-order kinetics**, where the elimination process is saturated, and the body eliminates a fixed amount of drug per unit of time, regardless of the plasma concentration. - In **first-order kinetics**, a **constant *fraction*** (not amount) is eliminated per unit time.
Question 8: A 55-year-old man presents with a tremor that occurs when his hands are at rest. He has a slow, shuffling gait and difficulty initiating movement. His symptoms improve with levodopa. What is the most likely diagnosis?
- A. Parkinson’s disease (Correct Answer)
- B. Huntington’s disease
- C. Essential tremor
- D. Multiple sclerosis
Explanation: ***Parkinson’s disease*** - The classic triad of symptoms—**resting tremor**, **bradykinesia** (difficulty initiating movement, shuffling gait), and **rigidity**—is highly characteristic of Parkinson's disease [1, 5]. - Significant improvement with **levodopa** is a hallmark of dopaminergic responsiveness seen in Parkinson's disease. *Huntington’s disease* - Characterized by **chorea** (involuntary, jerky movements), cognitive decline, and psychiatric symptoms, which are not described in this patient. - The onset is typically earlier, and the tremor is not primarily a resting tremor. *Essential tremor* - Primarily an **action tremor** [1] that occurs during voluntary movement, unlike the resting tremor described in the patient. - While it can be debilitating, it typically does not present with **bradykinesia** or **shuffling gait**. *Multiple sclerosis* - A demyelinating disease presenting with a wide range of neurological symptoms depending on lesion location, such as sensory disturbances, weakness, visual problems, and **ataxia**. - While tremors can occur (often intention tremors), the clinical presentation of a **resting tremor**, **shuffling gait**, and **bradykinesia** is not typical of MS.
Question 9: Which one of the following causes low-volume erythrocytosis?
- A. High altitude
- B. Polycythemia Rubra Vera
- C. Gaisbock's syndrome (Correct Answer)
- D. Exogenous testosterone therapy
Explanation: ***Gaisbock's syndrome*** - **Gaisbock's syndrome**, also known as **stress erythrocytosis** or **relative polycythemia**, is characterized by a high hematocrit due to reduced plasma volume rather than an absolute increase in red blood cell (RBC) mass. - It is often associated with **hypertension**, **obesity**, and **stress**, predominantly affecting middle-aged men with a normal total erythrocyte mass [1]. *High altitude* - Living at **high altitudes** can cause **secondary erythrocytosis** due to chronic hypoxia, leading to increased erythropoietin production and an absolute increase in red blood cell mass [2]. - This is a **true erythrocytosis**, where both red blood cell count and total blood volume are elevated. *Polycythemia Rubra Vera* - **Polycythemia vera** is a **myeloproliferative neoplasm** causing an absolute increase in the red blood cell mass, resulting from uncontrolled production by the bone marrow. - It is characterized by a **JAK2V617F mutation** and leads to increased total blood volume, not reduced plasma volume [1]. *Exogenous testosterone therapy* - **Exogenous testosterone therapy** can stimulate erythropoiesis, leading to an **increase in red blood cell mass** and hematocrit, which is a form of **secondary erythrocytosis**. - This effect is mediated by increased erythropoietin production and is an absolute increase in RBCs, not a low-volume condition.
Question 10: A diabetic female on Isoniazid (INH) and Rifampicin for tuberculosis developed Deep Vein Thrombosis (DVT). She was started on Warfarin, but her Prothrombin Time (PT) is not elevated. What is the next appropriate step in management?
- A. Increase the dose of Warfarin
- B. Replace Warfarin with Acenocoumarol
- C. Switch Ethambutol for Rifampicin
- D. Use Low Molecular Weight Heparin (LMWH) (Correct Answer)
Explanation: ### Explanation **1. Why LMWH is the Correct Choice:** The patient is taking **Rifampicin**, a potent **cytochrome P450 (CYP3A4 and CYP2C9) enzyme inducer**. Warfarin is metabolized by these enzymes; therefore, Rifampicin significantly increases Warfarin metabolism, leading to subtherapeutic levels and a failure to elevate the Prothrombin Time (PT/INR). In the acute management of DVT, achieving rapid and reliable anticoagulation is critical [1]. Since the drug interaction makes Warfarin unpredictable and difficult to titrate, switching to **Low Molecular Weight Heparin (LMWH)** is the most appropriate step. LMWH does not rely on the CYP450 system and provides immediate, predictable anticoagulation [2]. **2. Analysis of Incorrect Options:** * **Option A (Increase Warfarin dose):** While theoretically possible, the induction effect of Rifampicin is so profound that extremely high doses of Warfarin would be required, making the INR highly unstable and increasing the risk of toxicity if Rifampicin is later discontinued. * **Option B (Replace with Acenocoumarol):** Acenocoumarol is also a Vitamin K antagonist metabolized by the liver; it shares the same metabolic pathways and drug interactions as Warfarin [1]. * **Option C (Switch Ethambutol for Rifampicin):** Rifampicin is a cornerstone of Short Course Chemotherapy (SCC) for TB. It should not be discontinued or replaced with a less potent drug like Ethambutol solely to accommodate Warfarin, as this risks treatment failure or MDR-TB. **3. NEET-PG High-Yield Pearls:** * **Rifampicin:** The "Great Inducer." It reduces the efficacy of Warfarin, Oral Contraceptive Pills (OCPs), Sulfonylureas, and Digoxin. * **Isoniazid (INH):** Conversely, INH is a CYP enzyme **inhibitor**, but in this clinical scenario, the inducing effect of Rifampicin dominates. * **Management Rule:** When a patient on Rifampicin requires anticoagulation, LMWH or Fondaparinux are preferred over Vitamin K antagonists due to predictable pharmacokinetics [2].
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free